• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

ObvioHealth Announces New Digital Biomarker Initiative For Subclinical Disease Trials


The company is teaming up with Singapore's Institute for Clinical Sciences on the initiative.

MQ-Illustrations, stock.adobe.com

ObvioHealth, a virtual research organization (VRO) announces a partnership with A*STAR's Singapore Institute for Clinical Sciences (SICS) to identify better and more sensitive ways to measure and capture health outcomes. A*STAR's SICS aims to identify biomarkers and associated treatments that can help populations manage subclinical symptoms more effectively.

"The proliferation of technology to capture health data has incentivized us to think more strategically about outcomes and how to measure them in new, more accurate ways," comments Craig Gravina, Chief Technology Officer at ObvioHealth. "Many people suffer from health conditions that are not sufficiently severe to be diagnosed using current methods and are therefore not eligible for interventions. We are pleased to collaborate with A*STAR's SICS to develop and validate more sensitive instruments that can bring relief to these populations."

The first project within this collaboration will be to study subclinical mood disturbances in the general population. The project seeks to identify new digital biomarkers of depressive and anxious feelings, as well as stress, that can be measured and applied in real life settings. Under the agreement, ObvioHealth will provide scientific input into study design as well as access to its ObvioGo platform for the management of participant data.

© 2024 MJH Life Sciences

All rights reserved.